Fu Dun Jack, Sharma Ishta, Farwana Reem, Faes Livia, Lascaratos Gerassimos, Gazzard Gus, Khawaja Anthony, Hammond Christopher, Kailani Obeda
Department of Ophthalmology, King's College London, London, UK.
UCL Institute of Ophthalmology, London, UK.
BMJ Open Ophthalmol. 2025 Jul 20;10(1):e002151. doi: 10.1136/bmjophth-2025-002151.
Report effectiveness of selective laser trabeculoplasty (SLT) and topical medical therapy for treatment initiation and escalation.
Multicentre, retrospective cohort study covering an observation period of 10 years.
Patients with ocular hypertension or primary open-angle glaucoma initiating intraocular pressure (IOP)-lowering therapy, or escalating from a single topical agent.
Kaplan-Meier estimate for duration of treatment success, defined by the time between treatment event to treatment failure, defined as meeting one of the following: a <20% reduction in IOP in comparison to baseline at two consecutive clinic visits; IOP >21 mm Hg at 2 consecutive clinic visits; or subsequent intensification of glaucoma treatment (subsequent increase in medical drops, SLT (re-)treatment, incisional glaucoma therapy).
A total of 4564 eyes (mean baseline IOP 21.8 SD 7.0 mm Hg) of 2708 patients were included. The median time to treatment failure (ie, duration for which treatment success can be expected for 50% of patients) was 1.72 years (95% CI 1.63 to 1.79) following initiation of a topical agent and 1.35 (95% CI 1.13 to 1.73) years after initial SLT.Following escalation in those already on a single topical agent, the median treatment failure time was 1.32 years (95% CI 1.23 to 1.44) for 2 topical agents and 1.53 years (95% CI 1.35 to 2.03) for a single topical agent and SLT.
This retrospective analysis reports the real-world effect of SLT and topical medical therapy on IOP and treatment success following the most common treatment scenarios: initiation of IOP-lowering treatment and intensification from a single topical drop. Due to the non-randomised nature of this study, it is not possible to draw firm conclusions regarding the comparative effectiveness of drop and SLT.
报告选择性激光小梁成形术(SLT)和局部药物治疗在治疗起始及升级方面的有效性。
多中心回顾性队列研究,观察期为10年。
开始进行降低眼压(IOP)治疗或从单一局部用药升级治疗的高眼压症或原发性开角型青光眼患者。
采用Kaplan-Meier法评估治疗成功的持续时间,治疗成功定义为从治疗开始到治疗失败的时间,治疗失败定义为符合以下任何一项:与连续两次门诊就诊时的基线相比,眼压降低<20%;连续两次门诊就诊时眼压>21 mmHg;或随后加强青光眼治疗(随后增加药物滴眼次数、SLT再次治疗、青光眼切开手术治疗)。
共纳入2708例患者的4564只眼(平均基线眼压21.8,标准差7.0 mmHg)。开始使用局部用药后,治疗失败的中位时间(即50%患者预期的治疗成功持续时间)为1.72年(95%CI 1.63至1.79),初次SLT治疗后为1.35年(95%CI 1.13至1.73)。在已经使用单一局部用药的患者升级治疗后,使用两种局部用药时治疗失败中位时间为1.32年(95%CI 1.23至1.44),使用单一局部用药加SLT时为1.53年(95%CI 1.35至2.03)。
这项回顾性分析报告了SLT和局部药物治疗在最常见治疗方案(降低眼压治疗起始及从单一局部滴眼药升级治疗)后对眼压及治疗成功的实际效果。由于本研究的非随机性质,无法就滴眼药和SLT的相对有效性得出确凿结论。